SELLAS Life Sciences hits 80th event in Phase 3 trial of GPS for acute myeloid leukemia, triggering final analysis.

SELLAS Life Sciences announced that its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients has reached the pre-specified 80th death event, triggering the final analysis of the study. This milestone allows the company to lock the database, unblind the data, and conduct statistical analysis of the primary endpoint, overall survival. SELLAS plans to report preliminary topline results this quarter, which could position GPS as a novel immunotherapy option for AML patients in second remission. The trial evaluates GPS as maintenance therapy, addressing a significant unmet need in AML treatment.

SELLAS Life Sciences Group Inc. has a market cap of $2.46 billion and an enterprise value of $2.32 billion as of Oct 28, 2026, 19:43 WIB. The stock price is USD 12.79, up 5.09% on the day, with a trading volume of 6,184,005 shares on Pluang. This trading activity reflects heightened investor interest coinciding with the announcement of the Phase 3 REGAL trial reaching its 80th event milestone.